TR200201752T2 - Dipeptid nitril katepsin K inhibitörleri. - Google Patents

Dipeptid nitril katepsin K inhibitörleri.

Info

Publication number
TR200201752T2
TR200201752T2 TR2002/01752T TR200201752T TR200201752T2 TR 200201752 T2 TR200201752 T2 TR 200201752T2 TR 2002/01752 T TR2002/01752 T TR 2002/01752T TR 200201752 T TR200201752 T TR 200201752T TR 200201752 T2 TR200201752 T2 TR 200201752T2
Authority
TR
Turkey
Prior art keywords
inhibitors
cathepsin
dipeptide nitrile
formula
nitrile cathepsin
Prior art date
Application number
TR2002/01752T
Other languages
English (en)
Inventor
Missbach Martin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200201752T2 publication Critical patent/TR200201752T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Içerisinde katepsin K' nin emplike oldugu bir hastalik veya tibbi durumun terapötik veya profilaktik tedavisi için faydali olan, formül (I)' deki dipeptid nitril Katepsin K inhibtörleri, ve bunlarin, farmasötik olarak kabul edilebilir tuzlar veya esterleri saglanmakta olup, söz konusu formül içerisindeki R1 ve R2; bagimsiz olarak H veya C1-C7 düsük alkidir, veya R1 ve R2, baglandiklari karbon atomu ile birlikte bir C3-C8 sikloalkil halkasini olusturmaktadir, ve Het; istege bagli olarak substitüsyonlu nitrojen-içeren bir heterosiklik substitüenttir.
TR2002/01752T 2000-02-10 2001-02-08 Dipeptid nitril katepsin K inhibitörleri. TR200201752T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003111.2A GB0003111D0 (en) 2000-02-10 2000-02-10 Organic compounds

Publications (1)

Publication Number Publication Date
TR200201752T2 true TR200201752T2 (tr) 2002-10-21

Family

ID=9885359

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01752T TR200201752T2 (tr) 2000-02-10 2001-02-08 Dipeptid nitril katepsin K inhibitörleri.

Country Status (31)

Country Link
US (4) US6642239B2 (tr)
EP (1) EP1254124B1 (tr)
JP (1) JP3942895B2 (tr)
KR (1) KR100544553B1 (tr)
CN (2) CN1183122C (tr)
AR (1) AR029466A1 (tr)
AT (1) ATE402930T1 (tr)
AU (1) AU764334B2 (tr)
BR (1) BR0108118A (tr)
CA (1) CA2396158C (tr)
CO (1) CO5261578A1 (tr)
CZ (1) CZ20022721A3 (tr)
DE (1) DE60135087D1 (tr)
ES (1) ES2310177T3 (tr)
GB (1) GB0003111D0 (tr)
HK (1) HK1050197A1 (tr)
HU (1) HUP0300148A3 (tr)
IL (1) IL150406A0 (tr)
MX (1) MXPA02007768A (tr)
MY (1) MY122826A (tr)
NO (1) NO20023780L (tr)
NZ (1) NZ519940A (tr)
PE (1) PE20020220A1 (tr)
PL (1) PL200119B1 (tr)
PT (1) PT1254124E (tr)
RU (2) RU2265601C2 (tr)
SK (1) SK11462002A3 (tr)
TR (1) TR200201752T2 (tr)
TW (1) TWI258473B (tr)
WO (1) WO2001058886A1 (tr)
ZA (1) ZA200206218B (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
DK1178958T3 (da) 1999-03-15 2004-06-21 Axys Pharm Inc N-cyanomethylamider som proteaseinhibitorer
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1383748A2 (en) 2000-12-22 2004-01-28 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2005504078A (ja) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
EP1446392A1 (en) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
BRPI0308208B8 (pt) * 2002-03-05 2021-05-25 Axys Pharm Inc compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos
EP1569954A1 (en) * 2002-12-05 2005-09-07 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
CN100393700C (zh) * 2003-06-30 2008-06-11 麦克弗罗斯特(加拿大)公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
AU2004262903B2 (en) * 2003-07-21 2007-08-23 Novartis Ag Combinations of a Cathepsin K inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
US20070135448A1 (en) * 2003-11-19 2007-06-14 Martin Missbach Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE461200T1 (de) 2004-01-08 2010-04-15 Medivir Ab Inhibitoren von cysteinprotease
CA2580501A1 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
EP1827472A4 (en) * 2004-12-06 2012-09-05 Univ California METHOD FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLS
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20090005323A1 (en) * 2005-01-19 2009-01-01 Michael David Percival Cathepsin K Inhibitors and Obesity
EP1841730A4 (en) * 2005-01-19 2010-10-27 Merck Frosst Canada Ltd CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) * 2005-08-30 2005-10-05 Novartis Ag Organic compounds
US8829209B2 (en) 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP3975226B2 (ja) * 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
EP2019688A2 (en) * 2006-05-22 2009-02-04 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in bone production
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
CN101970007A (zh) 2007-06-08 2011-02-09 日本化学医药株式会社 脑动脉瘤的治疗或预防药
BRPI0702541A2 (pt) 2007-06-21 2009-02-10 Petroleo Brasileiro Sa processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
US20100331545A1 (en) 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
US20100298507A1 (en) * 2009-05-19 2010-11-25 Menschig Klaus R Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
KR20140034821A (ko) 2011-05-16 2014-03-20 바이엘 인텔렉쳐 프로퍼티 게엠베하 폐고혈압 및/또는 심부전의 치료 및/또는 예방을 위한 카텝신 k 억제의 용도
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9593138B2 (en) 2012-10-05 2017-03-14 Wayne State University Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
US9481707B2 (en) 2013-06-14 2016-11-01 Seikagaku Corporation α-oxoacyl amino-caprolactam derivative
WO2014199645A1 (ja) 2013-06-14 2014-12-18 生化学工業株式会社 α－オキソアシルアミノカプロラクタム体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
EP0648740B1 (en) 1993-04-28 1997-10-08 Kumiai Chemical Industry Co., Ltd. Amino acid amide derivative, agrohorticultural bactericide, and production process
JPH09501420A (ja) * 1993-07-30 1997-02-10 スミスクライン・ビーチャム・コーポレイション ３−シアノ−３−（３，４−二置換）フェニルシクロヘキシル−１−カルボキシレート類
AU691201B2 (en) 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
WO1995024382A1 (en) 1994-03-10 1995-09-14 G.D. Searle & Co. L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
JPH11505522A (ja) 1995-04-21 1999-05-21 ノバルティス・アクチエンゲゼルシャフト エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
IL129504A0 (en) 1996-11-22 2000-02-29 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino acid amides pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
TR200001189T2 (tr) 1997-11-05 2000-09-21 Novartis Ag. Dipeptid nitriller.
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
EP1155011A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
WO2000049007A1 (en) 1999-02-20 2000-08-24 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
DK1178958T3 (da) 1999-03-15 2004-06-21 Axys Pharm Inc N-cyanomethylamider som proteaseinhibitorer
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
WO2001019808A1 (en) * 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
JP2001139320A (ja) * 1999-11-05 2001-05-22 Asahi Glass Co Ltd 球状シリカゲルの製造方法
WO2001047886A1 (en) * 1999-12-24 2001-07-05 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin k inhibitors
ATE387199T1 (de) * 2000-01-06 2008-03-15 Merck Frosst Canada Ltd Neue substanzen und verbindungen als protease- inhibitoren
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2001058886A1 (en) 2001-08-16
US20030203919A1 (en) 2003-10-30
ZA200206218B (en) 2003-08-05
JP2003522764A (ja) 2003-07-29
RU2002123350A (ru) 2004-01-10
AR029466A1 (es) 2003-07-02
NZ519940A (en) 2004-02-27
MXPA02007768A (es) 2002-10-11
EP1254124B1 (en) 2008-07-30
PT1254124E (pt) 2008-11-03
US6642239B2 (en) 2003-11-04
KR100544553B1 (ko) 2006-01-24
AU4642601A (en) 2001-08-20
RU2293732C2 (ru) 2007-02-20
US20070191392A1 (en) 2007-08-16
DE60135087D1 (de) 2008-09-11
JP3942895B2 (ja) 2007-07-11
HK1050197A1 (en) 2003-06-13
HUP0300148A2 (en) 2003-05-28
GB0003111D0 (en) 2000-03-29
NO20023780D0 (no) 2002-08-09
RU2005108133A (ru) 2006-09-10
CZ20022721A3 (cs) 2002-11-13
ES2310177T3 (es) 2009-01-01
US20050267129A1 (en) 2005-12-01
SK11462002A3 (sk) 2003-01-09
CA2396158A1 (en) 2001-08-16
ATE402930T1 (de) 2008-08-15
RU2265601C2 (ru) 2005-12-10
PL357901A1 (en) 2004-07-26
CN1183122C (zh) 2005-01-05
NO20023780L (no) 2002-08-09
PE20020220A1 (es) 2002-03-25
CO5261578A1 (es) 2003-03-31
IL150406A0 (en) 2002-12-01
BR0108118A (pt) 2003-02-25
TWI258473B (en) 2006-07-21
US20010016207A1 (en) 2001-08-23
MY122826A (en) 2006-05-31
CN1636980A (zh) 2005-07-13
AU764334B2 (en) 2003-08-14
PL200119B1 (pl) 2008-12-31
EP1254124A1 (en) 2002-11-06
CA2396158C (en) 2010-02-02
CN1398260A (zh) 2003-02-19
HUP0300148A3 (en) 2005-04-28
KR20020072310A (ko) 2002-09-14

Similar Documents

Publication Publication Date Title
TR200201752T2 (tr) Dipeptid nitril katepsin K inhibitörleri.
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
RU2436780C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
TW200745032A (en) Novel heterobicyclic derivatives
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
EE200200603A (et) Dipeptidüüli peptidaasi IV inhibiitorid
JO2282B1 (en) Oxazole derivatives
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
HRP20090264T1 (en) Phenyl-piperazin methanone derivatives
MXPA05009855A (es) Derivados de guanidina y sus usos como antagonistas del receptor de neuropeptido ff.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
DK0397364T3 (da) Heterocycliske guandiner som 5HT3-antagonister
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate